ResMed’s chief commercial officer sells $2.33 million in stock

SAN DIEGO—Kaushik Ghoshal, the Chief Commercial Officer of SaaS at ResMed Inc . (NYSE:RMD), a $33.2 billion medical device company with a perfect Piotroski Score and GREAT financial health according to InvestingPro, disclosed the sale of company stock valued at approximately $2.33 million, according to a recent SEC filing. The transaction, executed on March 10, involved the sale of 9,745 shares at an average price of $239.31 per share. This sale was part of a series of trades conducted under a pre-established trading plan. The stock currently trades at $225.79, with InvestingPro analysis suggesting the shares are slightly undervalued relative to their Fair Value.

In addition to the sale, Ghoshal also exercised stock options, acquiring a total of 9,745 shares at prices ranging from $146.34 to $211.76 per share, totaling approximately $1.82 million. These transactions were executed under a Rule 10b5-1 plan, which allows insiders to set up a predetermined schedule for selling company stock.

Following these transactions, Ghoshal retains direct ownership of 9,725 shares of ResMed common stock. The filing also indicates indirect ownership of 9,628 shares through the Kaushik Ghoshal and Jayati Ghoshal Family Trust. For deeper insights into ResMed’s valuation and 12 additional ProTips, including its strong return metrics and moderate debt levels, explore the comprehensive Pro Research Report available on InvestingPro.

In other recent news, ResMed reported its Q2 FY2025 earnings, surpassing analyst expectations with an earnings per share (EPS) of $2.43, compared to the forecasted $2.32. The company also exceeded revenue projections, posting $1.28 billion against the anticipated $1.27 billion. Despite these strong financial results, ResMed’s stock experienced a decline in after-hours trading. Additionally, ResMed was added to Goldman Sachs’ APAC Director’s Cut Conviction List, reflecting a positive outlook for the company’s growth potential. Goldman Sachs expects ResMed to continue expanding its market share and achieve operating margin expansion. Meanwhile, Citi analysts upgraded ResMed’s stock rating from Neutral to Buy, citing strong expected earnings growth and robust free cash flow. On the other hand, Stifel analysts maintained a Hold rating on ResMed but lowered the price target due to concerns about the CPAP market amid the rising use of GLP-1 drugs. These developments highlight the mixed sentiment among analysts regarding ResMed’s future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.